Study of drugs for high-risk early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is hormone receptor-positive (estrogen or progesterone receptor positive) and HER2-negative.
- Your cancer is considered high-risk, such as having a tumor larger than 5 cm, high grade, or cancer spread to four or more lymph nodes.
- You are receiving or planning to receive abemaciclib, olaparib, and hormone therapy as prescribed by your doctor.
- You have not had another cancer needing active treatment in the last five years (some non-invasive cancers are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.